Evidence map›Paper›PMID 31465444›Full record

ArticlePloS one2019

Exploring the role of the various methionine residues in the Escherichia coli CusB adapter protein.

Aviv Meir, Gulshan Walke, Fabian Schwerdtfeger, Lada Gevorkyan Airapetov, Sharon Ruthstein

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aviv MeirDepartment of Chemistry; Bar-Ilan University, Ramat Gan, Israel.
Gulshan WalkeDepartment of Chemistry; Bar-Ilan University, Ramat Gan, Israel.
Fabian SchwerdtfegerDepartment of Chemistry; Bar-Ilan University, Ramat Gan, Israel.
Lada Gevorkyan AirapetovDepartment of Chemistry; Bar-Ilan University, Ramat Gan, Israel.
Sharon RuthsteinDepartment of Chemistry; Bar-Ilan University, Ramat Gan, Israel.ORCID 0000-0002-1741-6892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dissemination of resistant pathogenic microbes has become one of the most challenging problems that modern medicine has faced. Developing novel drugs based on new molecular targets that previously were not targeted, is therefore the highest priority in antibiotics research. One approach that has been recently suggested is to inhibit copper transporters in prokaryotic systems. Copper is required for many biological pathways, but sometimes it can harm the cell. Pathogenic systems have a highly sophisticated copper-regulation network; therefore, a better understanding of how this network operates at the molecular level should assist in developing the next generation of antibiotics. The CusB protein is part of the CusCBA periplasmic Cu(I) efflux system in Gram-negative bacteria, and was recently reported to play a key role in the functioning of the whole CusCBA system, in which conformational changes as well as the assembly/disassembly process control the opening of the transporter. More knowledge of the underlying mechanism is needed to attain a full understanding of CusB functioning, which is associated with targeting specific and crucial residues in CusB. Here, we combine in-vitro structural measurements, which use EPR spectroscopy and UV-Vis measurements, with cell experiments to explore the role of the various methionine residues in CusB. We targeted two methionine residues (M227 and M241) that are essential for the proper functioning of CusB.

Indexed as

Cell SurvivalCopperEscherichia coliEscherichia coli ProteinsMembrane Transport ProteinsMethionineModels, MolecularMutationProtein DomainsStress, PhysiologicalCopperCusB protein, E coliEscherichia coli ProteinsMembrane Transport ProteinsMethionine

Identifiers

PMID31465444
PMCPMC6715271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.